EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity

Edoardo Luigi Maria Mollero iD, Ivan Dozzani iD, Emilia Biamonte iD, Giulia Bendotti iD, Paolo Marzullo iD, Gianluca Aimaretti, Marco Gallo iD

Nutrients · 14.08.2026 · 18 (16) · 2654

DOI: 10.3390/nu18162654 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 14.08.2026. Verfasst von Edoardo Luigi Maria Mollero und 6 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology and Metabolic Diseases Unit, Department of Internal Medicine and Emergency Medicine, IRCCS AOU "SS Antonio e Biagio e Cesare Arrigo", V…. Hauptthemen laut MEDLINE: Muscle, Skeletal, Incretins, Weight Loss, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Incretin-based therapies (IBTs), including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 receptor agonists (GIP/GLP-1 RAs), have transformed the management of obesity and type 2 diabetes mellitus (T2DM). Although these agents provide substantial metabolic and cardiometabolic benefits, their effects on skeletal muscle, particularly in older adults at increased risk of sarcopenia and functional decline, remain incompletely understood.

Methods

This narrative review synthesizes evidence from randomized controlled trials (RCTs) and observational studies evaluating the effects of semaglutide and tirzepatide on skeletal muscle mass (SMM), muscle quality, strength, and physical performance. Current evidence on nutritional and exercise strategies aimed at preserving skeletal muscle during IBT was also reviewed.

Results

Both semaglutide and tirzepatide induce substantial weight loss accompanied by reductions in lean body mass (LBM). However, current evidence indicates that LBM loss is generally proportional to the magnitude of weight loss and should not be interpreted as a direct surrogate for skeletal muscle loss or drug-induced myotoxicity. Tirzepatide appears to improve skeletal muscle composition by reducing muscle fat infiltration (MFI), whereas semaglutide shows more heterogeneous effects on muscle strength and physical performance, particularly in older or frail individuals. Emerging evidence highlights the importance of muscle quality, nutritional adequacy, and resistance exercise as key determinants of muscle preservation, although functional outcomes and data in older adults remain limited.

Conclusions

The effects of incretin-based therapies (IBTs) on skeletal muscle are multifactorial and influenced by age, baseline muscle reserve, nutritional status, and physical activity. Preserving skeletal muscle health should be considered an integral component of obesity management through individualized nutritional care, adequate protein intake, resistance exercise, and regular functional assessment. Future research should prioritize the standardized evaluation of muscle quality and function and determine whether targeted nutritional interventions can improve the quality of weight loss and support healthy aging during IBT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscle, SkeletalIncretinsWeight LossDiabetes Mellitus, Type 2ObesityGlucagon-Like PeptidesHumansSemaglutideTirzepatideSarcopeniaMuscle Strength

Stichwörter der Autor:innen

GLP-1 receptor agonistsmuscle qualitynutritionobesityresistance trainingsarcopeniasemaglutideskeletal muscletirzepatidetype 2 diabetes

Substanzen

SemaglutideIncretinsTirzepatideGlucagon-Like Peptides

Autor:innen und Institutionen

  • Endocrinology and Metabolic Diseases Unit, Department of Internal Medicine and Emergency Medicine, IRCCS AOU "SS Antonio e Biagio e Cesare Arrigo", Via Venezia, 16, 15121 Alessandria, Italy.
  • Department of Statistics, Computer Science, Applications "Giuseppe Parenti", University of Florence, Viale Giovanni Battista Morgagni 59, 50134 Firenze, Italy.
  • Independent Researcher, 50142 Firenze, Italy.
  • Division of Endocrinology, Department of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy.
  • Division of Endocrinology and Metabolism, Department of Medical Sciences, University of Turin, Corso Dogliotti 14, 10126 Torino, Italy.

ORCID-Profile: Edoardo Luigi Maria Mollero, Ivan Dozzani, Emilia Biamonte, Giulia Bendotti, Paolo Marzullo, Marco Gallo

Zitieren

APA

Mollero, E. L. M., Dozzani, I., Biamonte, E., Bendotti, G., Marzullo, P., Aimaretti, G., & Gallo, M. (2026). Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity. Nutrients, 18(16), 2654. https://doi.org/10.3390/nu18162654

Vancouver

Mollero ELM, Dozzani I, Biamonte E, Bendotti G, Marzullo P, Aimaretti G, et al. Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity. Nutrients. 2026;18(16):2654. doi:10.3390/nu18162654

BibTeX
@article{Mollero2026,
  author = {Mollero, Edoardo Luigi Maria and Dozzani, Ivan and Biamonte, Emilia and Bendotti, Giulia and Marzullo, Paolo and Aimaretti, Gianluca and Gallo, Marco},
  title = {Beyond Weight Loss: Skeletal Muscle Health During Incretin-Based Therapy in Patients with Diabesity},
  journal = {Nutrients},
  year = {2026},
  volume = {18},
  number = {16},
  pages = {2654},
  doi = {10.3390/nu18162654}
}
Kostenlos starten →